• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Genetic polymorphism at as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma.作为弥漫性大B细胞淋巴瘤患者利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松疗效预测指标的基因多态性
Haematologica. 2017 May;102(5):e199-e202. doi: 10.3324/haematol.2016.159087. Epub 2017 Feb 2.
2
Association of BAX G(-248)A and BCL2 C(-717)A polymorphisms with outcome in diffuse large B-cell lymphoma patients.BAX基因G(-248)A多态性和BCL2基因C(-717)A多态性与弥漫性大B细胞淋巴瘤患者预后的相关性
Br J Haematol. 2017 May;177(4):650-654. doi: 10.1111/bjh.14089. Epub 2016 Apr 21.
3
R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433.R-CHOP 联合碘-131 托西莫单抗巩固治疗晚期弥漫性大 B 细胞淋巴瘤（DLBCL）：SWOG S0433。
Br J Haematol. 2014 Aug;166(3):382-9. doi: 10.1111/bjh.12906. Epub 2014 Apr 18.
4
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.免疫组化双打击评分是利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗弥漫性大 B 细胞淋巴瘤患者预后的强有力预测指标。
J Clin Oncol. 2012 Oct 1;30(28):3460-7. doi: 10.1200/JCO.2011.41.4342. Epub 2012 Jun 4.
5
Outcomes with R-CEOP for R-CHOP-ineligible patients with diffuse large B-cell lymphoma are highly dependent on cell of origin defined by Hans criteria.对于不符合R-CHOP治疗标准的弥漫性大B细胞淋巴瘤患者，采用R-CEOP方案的治疗结果高度依赖于根据汉斯标准定义的起源细胞。
Leuk Lymphoma. 2016 May;57(5):1191-3. doi: 10.3109/10428194.2015.1096356. Epub 2015 Oct 20.
6
Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas.MYC/BCL2免疫组化在弥漫性大B细胞淋巴瘤中的重要性日益凸显。
J Clin Oncol. 2012 Oct 1;30(28):3433-5. doi: 10.1200/JCO.2012.44.4729. Epub 2012 Sep 4.
7
Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.皮下和静脉注射利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松在一线弥漫性大 B 细胞淋巴瘤中的疗效和安全性：随机 MabEase 研究。
Haematologica. 2017 Nov;102(11):1913-1922. doi: 10.3324/haematol.2017.173583. Epub 2017 Sep 21.
8
Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial.聚乙二醇化脂质体阿霉素在老年弥漫性大B细胞淋巴瘤患者标准R-CHOP化疗中替代传统阿霉素的开放标签、单臂、II期试验。
Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):152-8. doi: 10.1016/j.clml.2014.09.001. Epub 2014 Sep 28.
9
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗弥漫性大 B 细胞淋巴瘤时 MYC 和 BCL2 的共表达。
J Clin Oncol. 2012 Oct 1;30(28):3452-9. doi: 10.1200/JCO.2011.41.0985. Epub 2012 Jul 30.
10
Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.对于老年弥漫性大 B 细胞淋巴瘤患者，采用低剂量 21 天周期利妥昔单抗和环磷酰胺、多柔比星、长春新碱和泼尼松治疗的疗效和耐受性。
Leuk Lymphoma. 2013 Nov;54(11):2441-7. doi: 10.3109/10428194.2013.780654. Epub 2013 Apr 17.

引用本文的文献

1
Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms.B细胞肿瘤患者基因组中罕见种系变异的检测
Cancers (Basel). 2021 Mar 16;13(6):1340. doi: 10.3390/cancers13061340.
2
Diffuse Large B-Cell Lymphoma's New Genomics: The Bridge and the Chasm.弥漫性大B细胞淋巴瘤的新基因组学：桥梁与鸿沟
J Clin Oncol. 2020 Oct 20;38(30):3565-3574. doi: 10.1200/JCO.20.01501. Epub 2020 Aug 19.

本文引用的文献

1
Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.免疫化疗治疗弥漫性大B细胞淋巴瘤无事件生存期的全基因组关联研究
J Clin Oncol. 2015 Nov 20;33(33):3930-7. doi: 10.1200/JCO.2014.60.2573. Epub 2015 Oct 12.
2
Comprehensive pathway-based analysis identifies associations of BCL2, GNAO1 and CHD2 with non-obstructive azoospermia risk.基于通路的综合分析确定了BCL2、GNAO1和CHD2与非梗阻性无精子症风险的关联。
Hum Reprod. 2014 Apr;29(4):860-6. doi: 10.1093/humrep/deu013. Epub 2014 Feb 18.
3
Candidate gene association study in pediatric acute lymphoblastic leukemia evaluated by Bayesian network based Bayesian multilevel analysis of relevance.基于关联的贝叶斯多层分析的候选基因关联研究在儿科急性淋巴细胞白血病中的评估。
BMC Med Genomics. 2012 Sep 28;5:42. doi: 10.1186/1755-8794-5-42.
4
BCL2 genetic variants are associated with acute kidney injury in septic shock*.BCL2 基因变异与感染性休克所致急性肾损伤相关*。
Crit Care Med. 2012 Jul;40(7):2116-23. doi: 10.1097/CCM.0b013e3182514bca.
5
Genetic variation in cell death genes and risk of non-Hodgkin lymphoma.细胞死亡基因的遗传变异与非霍奇金淋巴瘤的风险。
PLoS One. 2012;7(2):e31560. doi: 10.1371/journal.pone.0031560. Epub 2012 Feb 7.
6
BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab.BCL2 预测了接受 CHOP 样治疗和利妥昔单抗治疗的生发中心 B 细胞样弥漫性大 B 细胞淋巴瘤患者的生存情况。
Clin Cancer Res. 2011 Dec 15;17(24):7785-95. doi: 10.1158/1078-0432.CCR-11-0267. Epub 2011 Sep 20.
7
BCL2 genotypes: functional and neurobehavioral outcomes after severe traumatic brain injury.BCL2 基因型：严重创伤性脑损伤后的功能和神经行为结果。
J Neurotrauma. 2010 Aug;27(8):1413-27. doi: 10.1089/neu.2009.1256.
8
Genome-wide association studies in diverse populations.全基因组关联研究在不同人群中的应用。
Nat Rev Genet. 2010 May;11(5):356-66. doi: 10.1038/nrg2760.
9
Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century.从20世纪90年代到21世纪初，被诊断为非霍奇金淋巴瘤的患者的治疗效果持续改善。
Arch Intern Med. 2008 Mar 10;168(5):469-76. doi: 10.1001/archinternmed.2007.125.
10
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.在预后良好的年轻弥漫性大B细胞淋巴瘤患者中，CHOP样化疗联合利妥昔单抗对比单纯CHOP样化疗：美罗华国际试验（MInT）组的一项随机对照试验
Lancet Oncol. 2006 May;7(5):379-91. doi: 10.1016/S1470-2045(06)70664-7.

Genetic polymorphism at as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma.

作者信息

Bashash Morteza, Connors Joseph M, Gascoyne Randy D, Meissner Barbara, Schuetz Johanna M, Leach Stephen, Slack Graham W, Berry Brian R, Hu Howard, Sehn Laurie H, Brooks-Wilson Angela R, Spinelli John J

机构信息

Department of Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada.

Dalla Lana School of Public Health, University of Toronto, ON, Canada.

出版信息

Haematologica. 2017 May;102(5):e199-e202. doi: 10.3324/haematol.2016.159087. Epub 2017 Feb 2.

DOI:10.3324/haematol.2016.159087
PMID:28154089
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5477624/
Abstract
摘要